As of 2015, the survival rate for those diagnosed with mantle cell lymphoma is five to six years, reports the MD Anderson Cancer Center. Mantle cell lymphoma is usually diagnosed in its late stages, after the cancer has spread to the gastrointestinal tract and bone marrow, states the Lymphoma Research Foundation.
Mantle cell lymphoma is a rare form of non-Hodgkin's lymphoma that originates in the mantle zone of the lymph node, reports the Lymphoma Research Foundation. Mantle cell lymphoma usually affects men over the age of 60. Depending on the patient, the lymphoma can either grow aggressively or it can slowly spread throughout the body. As of 2015, mantle cell lymphoma represents 6 percent of all diagnosed non-Hodgkin's lymphomas, states the MD Anderson Cancer Center.
Only about 20 percent of mantle cell lymphoma patients present symptoms, such as fever, sweats or weight loss, reports the MD Anderson Cancer Center. However, these patients do report a lump somewhere in their bodies.
Treatment for mantle cell lymphoma often includes combination chemotherapy with the monoclonal antibody rituximab, states the Lymphoma Research Foundation. Later, patients are often given an autologous stem cell transplant. However, these treatments are usually reserved for younger patients with aggressive forms of mantle cell lymphoma. Doctors often only monitor those patients without symptoms and those with indolent forms of the cancer.